KR20220048051A - 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도 - Google Patents

고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도 Download PDF

Info

Publication number
KR20220048051A
KR20220048051A KR1020227011822A KR20227011822A KR20220048051A KR 20220048051 A KR20220048051 A KR 20220048051A KR 1020227011822 A KR1020227011822 A KR 1020227011822A KR 20227011822 A KR20227011822 A KR 20227011822A KR 20220048051 A KR20220048051 A KR 20220048051A
Authority
KR
South Korea
Prior art keywords
patients
ser
patient
week
ldl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227011822A
Other languages
English (en)
Korean (ko)
Inventor
마리 바카라-디네
로렝스 베작
우메쉬 차우드하리
코린 하노텡
로버트 씨. 포디
윌리엄 제이. 새시엘라
대니얼 에이. 슈웨머 가이프
Original Assignee
사노피 바이오테크놀로지
리제너론 파아마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피 바이오테크놀로지, 리제너론 파아마슈티컬스, 인크. filed Critical 사노피 바이오테크놀로지
Priority to KR1020237026483A priority Critical patent/KR20230119045A/ko
Publication of KR20220048051A publication Critical patent/KR20220048051A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
KR1020227011822A 2013-10-11 2014-10-10 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도 Ceased KR20220048051A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237026483A KR20230119045A (ko) 2013-10-11 2014-10-10 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US201361890154P 2013-10-11 2013-10-11
US61/890,154 2013-10-11
US201461923103P 2014-01-02 2014-01-02
US61/923,103 2014-01-02
US201461955514P 2014-03-19 2014-03-19
US61/955,514 2014-03-19
US201462004620P 2014-05-29 2014-05-29
US62/004,620 2014-05-29
US201462025104P 2014-07-16 2014-07-16
US62/025,104 2014-07-16
EP14306221 2014-07-31
EP14306221.4 2014-07-31
US201462054571P 2014-09-24 2014-09-24
US62/054,571 2014-09-24
EP14306584.5 2014-10-09
EP14306584 2014-10-09
PCT/US2014/060109 WO2015054619A2 (en) 2013-10-11 2014-10-10 Use of a pcsk9 inhibitor to treat hyperlipidemia
KR1020167012099A KR20160062166A (ko) 2013-10-11 2014-10-10 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167012099A Division KR20160062166A (ko) 2013-10-11 2014-10-10 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237026483A Division KR20230119045A (ko) 2013-10-11 2014-10-10 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도

Publications (1)

Publication Number Publication Date
KR20220048051A true KR20220048051A (ko) 2022-04-19

Family

ID=52813751

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227011822A Ceased KR20220048051A (ko) 2013-10-11 2014-10-10 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도
KR1020237026483A Ceased KR20230119045A (ko) 2013-10-11 2014-10-10 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도
KR1020167012099A Ceased KR20160062166A (ko) 2013-10-11 2014-10-10 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020237026483A Ceased KR20230119045A (ko) 2013-10-11 2014-10-10 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도
KR1020167012099A Ceased KR20160062166A (ko) 2013-10-11 2014-10-10 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도

Country Status (14)

Country Link
US (1) US20150140002A1 (https=)
EP (2) EP3055333B1 (https=)
JP (2) JP6846931B2 (https=)
KR (3) KR20220048051A (https=)
CN (3) CN115192704A (https=)
AU (2) AU2014331754B2 (https=)
CA (1) CA2926942A1 (https=)
EA (1) EA037526B1 (https=)
ES (1) ES2914978T3 (https=)
IL (1) IL244995B (https=)
MX (3) MX373298B (https=)
PL (2) PL3055333T4 (https=)
TW (1) TWI669131B (https=)
WO (1) WO2015054619A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
PL3395836T3 (pl) 2011-01-28 2021-12-13 Sanofi Biotechnology Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2992345T3 (es) 2011-09-16 2024-12-11 Regeneron Pharma Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9)
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US10058630B2 (en) * 2012-10-22 2018-08-28 Concievalve, Llc Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TW202021614A (zh) 2013-06-07 2020-06-16 法商賽諾菲生物技術公司 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
MX2016006226A (es) 2013-11-12 2016-09-07 Sanofi Biotechnology Regimenes de dosificacion para uso con inhibidores de pcsk9.
AU2015289874A1 (en) * 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
PL3169353T3 (pl) 2014-07-16 2020-06-01 Sanofi Biotechnology SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
EP3283012A4 (en) * 2015-04-15 2018-11-21 Concievalve LLC Devices and methods for inhibiting stenosis, obstruction, or calcification of a native heart valve, stented heart valve or bioprosthesis
CN104861071B (zh) * 2015-04-27 2019-04-12 南京师范大学 针对pcsk9的全人源单克隆抗体的可变区基因及其应用
JP2018523684A (ja) * 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
EP3515950A4 (en) 2016-09-20 2020-10-28 Wuxi Biologics Ireland Limited. NEW ANTI-PCSK9 ANTIBODIES
BR112019020148A2 (pt) 2017-04-13 2020-05-05 Cadila Healthcare Limited peptídeo
US20200131576A1 (en) 2017-04-25 2020-04-30 The Brigham And Women's Hospital, Inc. IL-8, IL-6, IL-1 Beta and TET2 and DNMT3A in Atherosclerosis
CN107090474A (zh) * 2017-05-22 2017-08-25 山东大学 一种腹主动脉瘤疾病动物模型的制备方法
CN109963877B (zh) * 2017-06-14 2023-01-20 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
CA3092936A1 (en) * 2018-03-06 2019-09-12 Sanofi Biotechnology Use of pcsk9 inhibitor for reducing cardiovascular risk
IL279363B2 (en) 2018-06-21 2025-12-01 Merck Sharp & Dohme Pcsk9 antagonist compounds
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
AU2020209216A1 (en) 2019-01-18 2021-08-26 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
BR112022009587A2 (pt) * 2019-11-18 2022-08-02 Ad Pharmaceuticals Co Ltd Anticorpo anti-pcsk9 e uso do mesmo
JP2023506732A (ja) * 2019-12-10 2023-02-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ホモ接合型家族性高コレステロール血症を処置するためのｐｃｓｋ９阻害剤の使用
US12577259B2 (en) 2019-12-20 2026-03-17 Merck Sharp & Dohme Llc PCSK9 antagonist compounds
CN114277032A (zh) * 2021-12-31 2022-04-05 华中科技大学同济医学院附属协和医院 一种低密度脂蛋白受体基因突变体及其应用
CN116983434B (zh) * 2023-09-28 2024-03-15 康霖生物科技（杭州）有限公司 用于基因治疗的核酸构建体及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20130064834A1 (en) * 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8357371B2 (en) * 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
PL3395836T3 (pl) * 2011-01-28 2021-12-13 Sanofi Biotechnology Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20130006482A1 (en) * 2011-06-30 2013-01-03 Ramadev Burigsay Hukkeri Guidance system for a mobile machine
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2992345T3 (es) * 2011-09-16 2024-12-11 Regeneron Pharma Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9)
TWI682780B (zh) * 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途

Also Published As

Publication number Publication date
JP2019214594A (ja) 2019-12-19
WO2015054619A3 (en) 2015-06-04
EA201690754A1 (ru) 2016-10-31
PL3055333T4 (pl) 2020-07-27
AU2014331754A1 (en) 2016-05-26
CN115154599A (zh) 2022-10-11
TW201605475A (zh) 2016-02-16
ES2914978T3 (es) 2022-06-20
CN115192704A (zh) 2022-10-18
PL3689913T3 (pl) 2022-07-04
EP3689913B1 (en) 2022-03-23
US20150140002A1 (en) 2015-05-21
AU2020203636A1 (en) 2020-06-25
EP3689913A1 (en) 2020-08-05
MX2022013172A (es) 2022-11-30
IL244995B (en) 2019-12-31
EP3055333A2 (en) 2016-08-17
WO2015054619A8 (en) 2016-03-31
AU2014331754B2 (en) 2020-06-18
CA2926942A1 (en) 2015-04-16
PL3055333T3 (pl) 2020-06-01
KR20160062166A (ko) 2016-06-01
TWI669131B (zh) 2019-08-21
EA037526B1 (ru) 2021-04-08
WO2015054619A2 (en) 2015-04-16
JP6994484B2 (ja) 2022-02-04
CN105814085A (zh) 2016-07-27
EP3055333B1 (en) 2019-12-04
KR20230119045A (ko) 2023-08-14
AU2020203636B2 (en) 2023-05-18
JP2016538248A (ja) 2016-12-08
IL244995A0 (en) 2016-05-31
MX2020004023A (es) 2020-08-13
MX373298B (es) 2020-05-20
JP6846931B2 (ja) 2021-03-24
MX2016004580A (es) 2016-12-08

Similar Documents

Publication Publication Date Title
AU2020203636B2 (en) Use of a PCSK9 inhibitor to treat hyperlipidemia
US12606638B2 (en) Dosing regimens for use with PCSK9 inhibitors
US20150231236A1 (en) Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
KR20220157516A (ko) 심혈관 위험을 감소시키는 방법
KR20170028441A (ko) 고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법
AU2016308111A1 (en) Anti-PCSK9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
TWI723478B (zh) Ｐｃｓｋ９抑制劑用於治療高血脂症的用途
HK40033729B (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
HK40033729A (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
HK1227890A1 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
HK1227890B (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
EA051213B1 (ru) Применение ингибитора pcsk9 для лечения гиперлипидемии

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220408

Application number text: 1020167012099

Filing date: 20160509

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220506

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220823

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230302

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220823

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20230802

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20230302

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2023101001675

Request date: 20230802

J301 Trial decision

Free format text: TRIAL NUMBER: 2023101001675; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20230802

Effective date: 20240530

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20240530

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20230802

Decision date: 20240530

Appeal identifier: 2023101001675